Clinical trial
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
NCT00035815 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00035815 |
|---|---|
| Title | Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial |
| Official title | Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Institute of Neurological Disorders and Stroke (NINDS) NIH ALS Association Cephalon Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis |
| Intervention type | Drug |
| Interventions | Insulin like growth factor, type 1, Placebo |
| Enrollment | 330 |
| Start date | Jun 1, 2003 |
| Primary completion | Aug 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 7, 2002 |
| Last update posted | Feb 15, 2013 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: